Perspective: Two ideas to increase innovation and reduce pharmaceutical costs and prices

Health Affairs

Volumn 28, Issue 1, 2009, Pages

  Jayadev, Arjun ^a   Stiglitz, Joseph ^b  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSUMER; DRUG COST; DRUG MARKETING; DRUG RESEARCH; REVIEW; SOCIAL WELFARE; SOCIOECONOMICS; ARTICLE; CLINICAL TRIAL; COST CONTROL; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; UNITED STATES;

CLINICAL TRIALS AS TOPIC; COST CONTROL; DRUG COSTS; DRUG INDUSTRY; FINANCING, GOVERNMENT; UNITED STATES;

EID: 59449108005     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.28.1.w165     Document Type: Review

References (9)

1. E. Berndt and D. Cutler, "Prescription Drug Spending Trends in the United States: Looking beyond the Turning Point," Health Affairs 28, no. 1 (2009): w151-w160 (published online 16 December 2008; 10.1377/hlthaff.28.1.w151).
2. N. Sood et al., "The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries," Health Affairs 28, no. 1 (2009): w125-w137 (published online 16 December 2008; 10.1377/hlthaff.28.1. w125);
3. and D.N. Lakdwalla et al., "U.S. Pharmaceutical Policy in a Global Marketplace," Health Affairs 28, no. 1 (2009): w138-w150 (published online 16 December 2008; 10.1377/hlthaff.28.1.w138).
4. F. Lichtenberg and T. Philipson, "The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry," Journal of Law and Economics 45, no. 2 (2002): 643-672.
5. D. Baker, "The Benefits and Savings of Publicly-Funded Clinical Trials of Prescription Drugs," Center for Economic Policy and Research Working Paper, March 2008, http://www.cepr.net/index.php/publications/reports/ the-benefits-and-savings-of-publicly-funded-clinical-trials-of-prescription- drugs (accessed 24 November 2008).
6. K. Claxton et al., "Value Based Pricing for NHS Drugs: An Opportunity Not to Be Missed?" BMJ 336, no. 7641 (2008): 251-254.
7. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski, "The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics 22, no. 2 (2003): 151-185.
8. T. Lewis, J. Reichman, and A. So, "The Case for Public Funding and Public Oversight of Clinical Trials," Economists' Voice 4, no. 1 (2007);
9. and Baker, "The Benefits and Savings."